Corporate Whistleblower Center Now Urges Pharmaceutical Reps Or Physicians With Proof Of Off-Label Drug Sales and Kickbacks To Call Them About Lucrative Reward Programs

Share Article

The Corporate Whistleblower Center is pointing to a recent multi-billion dollar settlement between the US Government and pharmaceutical giant Johnson & Johnson as encouragement for whistleblowers with proof of illegal kickbacks and off-label sales to contact them about rewards at 866-714-6466. Under the False Claims Act, individuals who step forward with substantial proof could be entitled to up to 15-30% of the settlement amount as a reward. http://CorporateWhistleblowerCenter.Com

News Image
The whistleblowers in this case, who came from a variety of states, received staggering awards of $112 million, $27.7 million, and $28 million

The Corporate Whistleblower Center says,“There are FDA rules designed to keep patients safe and informed about the potential dangers of prescription drugs. When pharmaceutical companies deliberately ignore these rules for their own gain, they put the health of their patients at risk. They also present opportunities for whistleblowers to step forward, do the right thing, and be rewarded handsomely as a result, as we would like to explain if a potential whistleblower calls us at 866-714-6466.”

According to a recent release from the Department of Justice, Johnson & Johnson agreed to pay $2.2 billion to settle allegations it promoted and encouraged the use of the drug Risperdal, an anti-psychotic approved only for schizophrenia, to elderly patients with dementia and children with mental disabilities, allegedly despite knowing it was not safe for these disorders. Allegedly many of these prescriptions were filled using Medicare funds. The lawsuit also alleged that that J&J and subsidiary Janssen paid illegal speaking fees to doctors, telling them they would only be paid if they increased sales of Risperdal. They also allegedly paid kickbacks to Omnicare, which dispenses prescriptions to nursing homes, for recommending their drugs.

The whistleblowers in this case, who came from a variety of states, received staggering awards of $112 million, $27.7 million, and $28 million.

“As you can see from this case, whistleblower rewards can be astronomical,” says the Corporate Whistleblower Center. “If you have proof a pharmaceutical company is involved in off-labeling and/or physician and pharmacy kickbacks, and you have well documented proof, contact us at 866-714-6466, so we can carefully explain federal whistleblower programs to you." http://CorporateWhistleblowerCenter.Com

Simple rules for a whistleblower from the Corporate Whistleblower Center:

  • Do not go to the government first if you are a major whistleblower. The Corporate Whistleblower Center says, “Major whistleblowers frequently go to the federal government thinking they will help. It’s a huge mistake.”
  • Do not go to the news media with your whistleblower information. Public revelation of a whistleblower’s information could destroy any prospect for a reward.
  • Do not try to force a government contractor, or corporation to come clean to the government about their wrongdoing. The Corporate Whistleblower Center says, “Fraud is so rampant among federal contractors that any suggestion of exposure might result in an instant job termination, or harassment of the whistleblower. Come to us first, tell us what type of information you have, and if we think it’s sufficient, we will help find the right law firms to assist in advancing your information.

Any type of insider or employee who possesses significant proof of their employer or a government contractor defrauding the federal government is encouraged to contact to Corporate Whistleblower Center anytime at 866-714-6466 or via their web site at http://CorporateWhistleBlowerCenter.Com

For attribution purposes please refer to the November 2013 press release regarding this matter.

Case number: U.S. ex rel. Starr v. Jansseen Pharmaceutical Products, L.P., No. 04-cv-1529, E.D. Pa.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

M Thomas Martin
Visit website